ArticleCost effectiveness and resource allocation : C/E2026
How much do lower respiratory tract infections in adults cost? A hospital-based cost analysis in Colombia.
Article in Cost effectiveness and resource allocation : C/E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn Colombia, lower respiratory tract infections (LRTI) are one of the main events of interest to public health. This study aims to describe and quantify the direct medical costs associated with hospital care for LRTI in the Colombian health system.
methodsA retrospective observational study using hospital and national databases was conducted to analyze the direct hospital costs of patients with LRTI from the perspective of the Colombian healthcare system. Data was obtained from hospital records and the Individual Registry of Health Services Provision (RIPS). Cost assessment was performed using national databases (Sufficiency for Health Benefits and the Drug Price Information System - SISMED). Costs were classified as follows: consultations, laboratory and imaging costs, procedures, medications, supplies, and hospital stay, segmented by age groups and diagnostic subgroups. The analysis used measures of central tendency and dispersion.
resultsThe services of 601 patients from a university hospital and 14,979 hospitalization cases registered in RIPS were analyzed. The findings revealed that costs are concentrated primarily in the population over 60 years of age, especially in treating influenza and pneumonia (J09-J18), accounting for more than 70% of the total cost. According to RIPS, the mean cost per hospitalized patient with LRTI was Int$5,657. At the university hospital, the median cost per patient was Int$7,525 (IQR Int$14,346). Medications and hospital stays were the largest components of the total cost. Additionally, respiratory syncytial virus (RSV) cases had mean hospital costs per patient of Int$7,340, with medications and hospital stays being the main cost drivers.
conclusionThe significant economic burden of LRTI on the Colombian health system, especially among adults over 60 years of age, highlights the need to strengthen public health policies aimed at their prevention and control. It is recommended to emphasize vaccination strategies, optimization of hospital management, and strengthening epidemiological surveillance. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.